Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.

Edgewise Therapeutics (EWTX) Short Interest Ratio & Short Volume

Edgewise Therapeutics logo
$31.44 -1.43 (-4.35%)
(As of 11/15/2024 08:54 PM ET)

Edgewise Therapeutics Short Interest Data

Edgewise Therapeutics (EWTX) has a short interest of 7.29 million shares, representing 12.19% of the float (the number of shares available for trading by the public). This marks a -14.13% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.2, indicating that it would take 6.2 days of the average trading volume of 953,202 shares to cover all short positions.

Current Short Interest
7,290,000 shares
Previous Short Interest
8,490,000 shares
Change Vs. Previous Month
-14.13%
Dollar Volume Sold Short
$244.73 million
Short Interest Ratio
6.2 Days to Cover
Last Record Date
October 31, 2024
Outstanding Shares
94,690,000 shares
Float Size
59,790,000 shares
Short Percent of Float
12.19%
Today's Trading Volume
933,000 shares
Average Trading Volume
953,202 shares
Today's Volume Vs. Average
98%
Skip Charts & View Short Interest History

EWTX Short Interest Over Time

EWTX Days to Cover Over Time

EWTX Percentage of Float Shorted Over Time

Edgewise Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/31/20247,290,000 shares $244.73 million -14.1%12.2%6.2 $33.57
10/15/20248,490,000 shares $280.09 million -9.1%14.3%7 $32.99
9/30/20249,340,000 shares $249.28 million +14.3%15.8%8.1 $26.69
9/15/20248,170,000 shares $153.84 million +5.0%14.0%6.8 $18.83
8/31/20247,780,000 shares $145.88 million +21.6%13.3%9 $18.75
8/15/20246,400,000 shares $120.77 million -20.8%11.0%7.6 $18.87
The Harvard Business School proved his stock picking system works (Ad)

If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it.

Follow this link here we’ll add you to the guest list.
7/31/20248,080,000 shares $137.60 million -5.8%13.6%9.8 $17.03
7/15/20248,580,000 shares $196.22 million +1.2%14.5%11.2 $22.87
6/30/20248,480,000 shares $152.72 million +11.3%14.3%11.5 $18.01
6/15/20247,620,000 shares $133.43 million +17.2%11.6%12.7 $17.51
5/31/20246,500,000 shares $111.35 million -1.4%9.9%9.6 $17.13
5/15/20246,590,000 shares $116.51 million +1.1%10.0%9.2 $17.68
4/30/20246,520,000 shares $116.97 million +13.2%10.4%8.9 $17.94
4/15/20245,760,000 shares $94.92 million +0.7%9.2%7.6 $16.48
3/31/20245,720,000 shares $104.33 million +27.7%9.1%5.7 $18.24
3/15/20244,480,000 shares $75.80 million -18.0%7.1%4.3 $16.92
2/29/20245,460,000 shares $89.16 million +6.4%9.1%5.6 $16.33
2/15/20245,130,000 shares $93.98 million -5.0%8.6%5.4 $18.32
1/31/20245,400,000 shares $96.28 million -33.9%11.5%6.3 $17.83
1/15/20248,170,000 shares $81.70 million -12.5%22.7%10.8 $10.00
12/31/20239,340,000 shares $102.18 million +9.9%25.9%20.1 $10.94
12/15/20238,500,000 shares $61.97 million +20.9%23.7%22.6 $7.29
11/30/20237,030,000 shares $42.74 million +11.1%19.6%24.7 $6.08
11/15/20236,330,000 shares $41.52 million +5.3%17.7%34.2 $6.56
10/31/20236,010,000 shares $38.46 million +4.5%17.0%35.9 $6.40
10/15/20235,750,000 shares $38.58 million +1.6%16.3%36.2 $6.71
9/30/20235,660,000 shares $32.43 million +2.2%16.1%33.2 $5.73
9/15/20235,540,000 shares $35.57 million +1.7%15.7%28.2 $6.42
8/31/20235,450,000 shares $34.06 million +1.1%13.9%26.9 $6.25
8/15/20235,390,000 shares $39.35 million -1.3%13.8%24.5 $7.30
7/31/20235,460,000 shares $39.80 million -12.1%13.7%24.8 $7.29
7/15/20236,210,000 shares $44.84 million +11.7%15.6%27.4 $7.22
6/30/20235,560,000 shares $43.09 million +3.5%14.0%26.4 $7.75
6/15/20235,370,000 shares $46.83 million +12.6%13.5%25 $8.72
5/31/20234,770,000 shares $48.27 million +5.8%12.0%25.3 $10.12
5/15/20234,510,000 shares $40.68 million +1.8%11.3%25.8 $9.02
4/30/20234,430,000 shares $38.85 million +6.2%11.0%25.6 $8.77
4/15/20234,170,000 shares $24.23 million +4.5%10.3%26.5 $5.81
3/31/20233,990,000 shares $26.61 million +6.1%9.9%25.1 $6.67
3/15/20233,760,000 shares $28.76 million -2.1%9.3%25.4 $7.65
The Harvard Business School proved his stock picking system works (Ad)

If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it.

Follow this link here we’ll add you to the guest list.
2/28/20233,840,000 shares $36.79 million +1.6%9.5%22.4 $9.58
2/15/20233,780,000 shares $37.76 million -2.3%9.3%21.3 $9.99
1/31/20233,870,000 shares $39.59 million +29.9%9.6%21.5 $10.23
1/15/20232,980,000 shares $32.93 million -25.7%7.4%15.8 $11.05
12/30/20224,010,000 shares $35.85 million +38.8%10.0%20 $8.94
12/15/20222,890,000 shares $22.46 million -16.2%7.2%13.3 $7.77
11/30/20223,450,000 shares $30.88 million -3.1%8.6%11.8 $8.95
11/15/20223,560,000 shares $37.38 million -1.1%8.9%12 $10.50
10/31/20223,600,000 shares $34.24 million +8.4%8.9%12.1 $9.51
10/15/20223,320,000 shares $34.59 million +19.0%10.4%10.9 $10.42
9/30/20222,790,000 shares $27.45 million +5.3%10.2%9.2 $9.84
9/15/20222,650,000 shares $24.19 million -12.3%9.7%8.3 $9.13
8/31/20223,020,000 shares $30.44 million -17.0%10.8%12.3 $10.08
8/15/20223,640,000 shares $39.17 million +3.7%13.1%14.7 $10.76
7/31/20223,510,000 shares $33.94 million +3.2%12.5%13.5 $9.67
7/15/20223,400,000 shares $34.54 million +9.0%12.1%13.3 $10.16
6/30/20223,120,000 shares $24.84 million -3.1%11.1%12.6 $7.96
6/15/20223,220,000 shares $19.90 million +1.6%11.5%13.2 $6.18
5/31/20223,170,000 shares $19.81 million -16.1%11.3%14.8 $6.25
5/15/20223,780,000 shares $29.60 million -3.3%13.6%16.7 $7.83
4/30/20223,910,000 shares $31.20 million +1.8%14.0%18.4 $7.98
4/15/20223,840,000 shares $33.48 million -5.9%13.8%16.5 $8.72
3/31/20224,080,000 shares $39.58 million -2.9%14.7%14.7 $9.70
3/15/20224,200,000 shares $42.97 million -10.6%15.1%10.8 $10.23
2/28/20224,700,000 shares $55.41 million +4.7%16.9%10.2 $11.79
2/15/20224,490,000 shares $58.95 million +12.5%18.6%9.8 $13.13
1/31/20223,990,000 shares $54.26 million +8.7%16.5%9.1 $13.60
1/15/20223,670,000 shares $64.23 million +4.6%N/A8.8 $17.50
12/31/20213,510,000 shares $53.63 million +31.0%14.5%9.2 $15.28
12/15/20212,680,000 shares $51.97 million +24.1%11.1%11.8 $19.39
11/30/20212,160,000 shares $37.63 million +45.0%8.9%16.8 $17.42
11/15/20211,490,000 shares $29.25 million +7.2%6.1%15.6 $19.63
10/29/20211,390,000 shares $22.94 million -12.0%5.9%16.7 $16.50
10/15/20211,580,000 shares $28.03 million No Change6.7%23.5 $17.74
9/30/20211,580,000 shares $26.23 million -1.3%6.7%17.2 $16.60
9/15/20211,600,000 shares $25.39 million -23.8%6.9%12.1 $15.87
8/31/20212,100,000 shares $33.26 million +2.4%9.0%12.6 $15.84
8/13/20212,050,000 shares $33.33 million No Change8.8%11 $16.26

EWTX Short Interest - Frequently Asked Questions

What is Edgewise Therapeutics' current short interest?

Short interest is the volume of Edgewise Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 7,290,000 shares of EWTX short. 12.19% of Edgewise Therapeutics' shares are currently sold short. Learn More on Edgewise Therapeutics' current short interest.

What is a good short interest ratio for Edgewise Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EWTX shares currently have a short interest ratio of 6.0. Learn More on Edgewise Therapeutics's short interest ratio.

Which institutional investors are shorting Edgewise Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Edgewise Therapeutics: Jane Street Group LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Edgewise Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.19% of Edgewise Therapeutics' floating shares are currently sold short.

Is Edgewise Therapeutics' short interest increasing or decreasing?

Edgewise Therapeutics saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 7,290,000 shares, a drop of 14.1% from the previous total of 8,490,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Edgewise Therapeutics' float size?

Edgewise Therapeutics currently has issued a total of 94,690,000 shares. Some of Edgewise Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Edgewise Therapeutics currently has a public float of 59,790,000 shares.

How does Edgewise Therapeutics' short interest compare to its competitors?

12.19% of Edgewise Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Edgewise Therapeutics: Dyne Therapeutics, Inc. (9.77%), Kura Oncology, Inc. (16.39%), AnaptysBio, Inc. (23.75%), Arcturus Therapeutics Holdings Inc. (18.50%), MaxCyte, Inc. (3.34%), Heron Therapeutics, Inc. (18.94%), Solid Biosciences Inc. (4.40%), Gossamer Bio, Inc. (2.78%), Vaxcyte, Inc. (7.16%), Dr. Reddy's Laboratories Limited (1.28%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

What does it mean to sell short Edgewise Therapeutics stock?

Short selling EWTX is an investing strategy that aims to generate trading profit from Edgewise Therapeutics as its price is falling. EWTX shares are trading down $1.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Edgewise Therapeutics?

A short squeeze for Edgewise Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EWTX, which in turn drives the price of the stock up even further.

How often is Edgewise Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EWTX, twice per month. The most recent reporting period available is October, 31 2024.




This page (NASDAQ:EWTX) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners